ECU Receives 3 New Patents

The Office of Innovation and New Ventures reported that the university received three new patents this summer. ECU received the following three issued U.S. patents:

U.S. Patent 10,363,306 (Issued July 30, 2019)

  • Cytokines and Neuroantigens for Treatment of Immune Disorders
  • Mark Mannie, Microbiology & Immunology
  • The rights have been licensed to ECU startup company T-Reg Therapeutics.

U.S. Patent 10,368,785 (Issued Sept. 6, 2019)

  • In-Ear Hearing Test Probe Devices and Methods and Systems Using Same
  • Gregg Givens, Communication Sciences & Disorders (retired)
  • Jianchu (Jason) Yao, Engineering

U.S. Patent 10,390,718 (Issued Sept. 27, 2019)

  • Multi-Spectral Physiologic Visualization (MSPV) Using Laser Imaging Methods and Systems for Blood Flow and Perfusion Imaging and Quantification in an Endoscopic Design
  • Cheng Chen and Ken Jacobs, Physics
  • Bruce Ferguson, Visiting Scientist
  • The rights have been licensed to ECU start-up company RFPi, Inc. RFPi also received a $1.49M Phase II STTR grant from the NIH to explore use of its iCertainty device in patients with peripheral artery disease. The devise received regulatory approval in December 2018 for use in open surgery procedures.